NICE rejects Novartis’ migraine prevention drug AimovigSome migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are Share XNICE rejects Novartis’ migraine prevention drug Aimovighttps://pharmaphorum.com/news/nice-rejects-novartis-migraine-prevention-drug-aimovig/
Lilly files new class migraine drug with FDAEli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its Share XLilly files new class migraine drug with FDAhttps://pharmaphorum.com/news/lilly-files-new-class-migraine-drug-with-fda/
Teva slumps after Express Scripts funds migraine rivals in USA major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in Share XTeva slumps after Express Scripts funds migraine rivals in UShttps://pharmaphorum.com/news/teva-slumps-after-express-scripts-funds-migraine-rivals-in-us/
Lilly pushes into migraine market as Emgality approved in USThe FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group Share XLilly pushes into migraine market as Emgality approved in UShttps://pharmaphorum.com/news/lilly-pushes-into-migraine-market-as-emgality-approved-in-us/
FDA approves Teva’s migraine drug, decision due on Lilly’s rivalThe FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns Share XFDA approves Teva’s migraine drug, decision due on Lilly’s rivalhttps://pharmaphorum.com/news/fda-approves-tevas-migraine-drug-decision-due-on-lillys-rival/
Value-based healthcare: What’s it worth to you?It takes healthy people to make a healthy society – and that must be taken into account when Share XValue-based healthcare: What’s it worth to you?https://pharmaphorum.com/views-and-analysis/value-based-healthcare-whats-worth/
Concerns over Teva migraine drug because of manufacturing issuesThere are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the Share XConcerns over Teva migraine drug because of manufacturing issueshttps://pharmaphorum.com/news/concerns-over-teva-migraine-drug-because-of-manufacturing-issues/
Breakthrough migraine prevention treatment approved in EuropeNovartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine Share XBreakthrough migraine prevention treatment approved in Europehttps://pharmaphorum.com/news/breakthrough-migraine-prevention-treatment-approved-in-europe/
Lilly joins CGRP race to cure migraineEli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the Share XLilly joins CGRP race to cure migrainehttps://pharmaphorum.com/news/lilly-joins-cgrp-race-to-cure-migraine/
